Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance

Molecular Metabolism

Volumn 2, Issue 3, 2013, Pages 142-152

  Chandarana, Keval ^a   Gelegen, Cigdem ^a   Irvine, Elaine E ^b   Choudhury, Agharul I ^b   Amouyal, Chloé ^c,d   Andreelli, Fabrizio ^c,d   Withers, Dominic J ^b   Batterham, Rachel L ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

GLP 1; Glucose homeostasis; PYY; Y2 receptor

Indexed keywords

EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y [28 LEUCINE 31 PROLINE]; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BARIATRIC SURGERY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN RELEASE; LIVER VEIN; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

MUS;

EID: 84883222261     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.03.001     Document Type: Article

References (46)

1. Drucker D.J. The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation 2007, 117:24-32.
2. Williams K.W., Elmquist J.K. From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nature Neuroscience 2012, 15:1350-1355.
3. Chandarana K., Batterham R.L. Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nature Medicine 2012, 18:668-669.
4. Tam C.S., Berthoud H.R., Bueter M., Chakravarthy M.V., Geliebter A., Hajnal A., et al. Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium. Obesity Reviews 2011, 12:984-994.
5. Chambers A.P., Jessen L., Ryan K.K., Sisley S., Wilson-Perez H.E., Stefater M.A., et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011, 141:950-958.
6. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
7. Asmar M., Hojberg P.V., Deacon C.F., Hare K., Holst J.J., Madsbad S. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regulatory Peptides 2010, 160:175-180.
8. Mentlein R., Dahms P., Grandt D., Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regulatory Peptides 1993, 49:133-144.
9. Blomqvist A.G., Herzog H. Y-receptor subtypes-how many more?. Trends in Neuroscience 1997, 20:294-298.
10. Chandarana K., Batterham R., Peptide Y.Y. Current Opinion in Endocrinology, Diabetes, and Obesity 2008, 15:65-72.
11. Batterham R.L., Heffron H., Kapoor S., Chivers J.E., Chandarana K., Herzog H., et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metabolism 2006, 4:223-233.
12. Boey D., Lin S., Karl T., Baldock P., Lee N., Enriquez R., et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006, 49:1360-1370.
13. Doods H., Gaida W., Wieland H.A., Dollinger H., Schnorrenberg G., Esser F., et al. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. European Journal of Pharmacology 1999, 384:R3-R5.
14. Abbott C.R., Small C.J., Kennedy A.R., Neary N.M., Sajedi A., Ghatei M.A., et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Research 2005, 1043:139-144.
15. Boey D., Sainsbury A., Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides 2007, 28:390-395.
16. Bottcher G., Ahren B., Lundquist I., Sundler F. Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 1989, 4:282-288.
17. van den Hoek A.M., Heijboer A.C., Corssmit E.P., Voshol P.J., Romijn J.A., Havekes L.M., et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 2004, 53:1949-1952.
18. Ortiz A.A., Milardo L.F., DeCarr L.B., Buckholz T.M., Mays M.R., Claus T.H., et al. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. Journal of Pharmacology and Experimental Therapeutics 2007, 323:692-700.
19. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. International Journal of Obesity and Related Metabolic Disorders 2004, 28:963-971.
20. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002, 418:650-654.
21. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine 2003, 349:941-948.
22. Sloth B., Holst J.J., Flint A., Gregersen N.T., Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. American Journal of Physiology-Endocrinology and Metabolism 2007, 292:E1062-E1068.
23. Choudhury A.I., Heffron H., Smith M.A., Al-Qassab H., Xu A.W., Selman C., et al. The role of insulin receptor substrate 2 in hypothalamic and beta cell function. Journal of Clinical Investigation 2005, 115:940-950.
24. Chu C.P., Kato K., Kunitake T., Watanabe S., Qiu D.L., Ueta Y., et al. Enhanced effects of central angiotensin II on cardiovascular and drinking responses in inbred polydipsic (STR/N) mice. Brain Research 2003, 962:129-134.
25. Cantley J., Burchfield J.G., Pearson G.L., Schmitz-Peiffer C., Leitges M., Biden T.J. Deletion of PKC{varepsilon} selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse {beta}-cells. Diabetes 2009.
26. Chandarana K., Gelegen C., Karra E., Choudhury A.I., Drew M.E., Fauveau V., et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 2011, 60:810-818.
27. Troy S., Soty M., Ribeiro L., Laval L., Migrenne S., Fioramonti X., et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metabolism 2008, 8:201-211.
28. Gelegen C., Chandarana K., Choudhury A.I., Al-Qassab H., Evans I.M., Irvine E.E., et al. Regulation of hindbrain Pyy expression by acute food deprivation, prolonged caloric restriction, and weight loss surgery in mice. American Journal of Physiology-Endocrinology and Metabolism 2012, 303:E659-E668.
29. Bertrand G., Gross R., Roye M., Ahren B., Ribes G. Evidence for a direct inhibitory effect of PYY on insulin secretion in rats. Pancreas 1992, 7:595-600.
30. Karlsson S., Ahren B. A role for islet peptide YY in the regulation of insulin secretion. Acta Physiologica Scandinavica 1996, 157:305-306.
31. Burcelin R., Brunner H., Seydoux J., Thorensa B., Pedrazzini T. Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides 2001, 22:421-427.
32. Nieuwenhuizen A.G., Karlsson S., Fridolf T., Ahren B. Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. Diabetologia 1994, 37:871-878.
33. Dumont Y., Moyse E., Fournier A., Quirion R. Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema. Journal of Molecular Neuroscience 2007, 33:294-304.
34. Huang X.F., Han M., Storlien L.H. The level of NPY receptor mRNA expression in diet-induced obese and resistant mice. Brain Research Molecular Brain Research 2003, 115:21-28.
35. Rahardjo G.L., Huang X.F., Tan Y.Y., Deng C. Decreased plasma peptide YY accompanied by elevated peptide YY and Y2 receptor binding densities in the medulla oblongata of diet-induced obese mice. Endocrinology 2007, 148:4704-4710.
36. Laferrere B. Diabetes remission after bariatric surgery: is it just the incretins?. International Journal of Obesity (London) 2011, 35(Suppl 3):S22-S25.
37. Scott W.R., Batterham R.L. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2011, 301:R15-R27.
38. Thaler J.P., Yi C.X., Schur E.A., Guyenet S.J., Hwang B.H., Dietrich M.O., et al. Obesity is associated with hypothalamic injury in rodents and humans. Journal of Clinical Investigation 2012, 122:153-162.
39. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 2007, 87:1409-1439.
40. Tolhurst G., Reimann F., Gribble F.M. Nutritional regulation of glucagon-like peptide-1 secretion. Journal of Physiology 2009, 587:27-32.
41. Goumain M., Voisin T., Lorinet A.M., Laburthe M. Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochemical and Biophysical Research Communications 1998, 247:52-56.
42. Wang L., Gourcerol G., Yuan P.Q., Wu S.V., Million M., Larauche M., et al. Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2010, 298:G45-G56.
43. Chelikani P.K., Haver A.C., Reidelberger R.D. Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2004, 287:R1064-R1070.
44. D'Alessio D., Lu W., Sun W., Zheng S., Yang Q., Seeley R., et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2007, 293:R2163-R2169.
45. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
46. Stadlbauer U., Arnold M., Weber E., Langhans W. Possible mechanisms of circulating PYY-induced satiation in male rats. Endocrinology 2013, 154:193-204.